. 2022 Jun;17(6):835–842. doi: 10.2215/CJN.16171221

Table 4.

Fractures at 180 and 365 days assessed by eGFR group

eGFR Group, ml/min per 1.73 m² and Medication	Fracture at 180 d, N (%)	Weighted Hazard Ratio (95% Confidence Interval)	P Value for Subgroup Interaction	Fracture at 365 d, N (%)	Weighted Hazard Ratio (95% Confidence Interval)	P Value for Subgroup Interaction
All
DPP-4i, n=37,449	172 (0.46)	0.95 (0.79 to 1.13)	N/A	360 (0.96)	0.88 (0.77 to 1.00)	N/A
SGLT2i, n=38,994	170 (0.44)	0.95 (0.79 to 1.13)	N/A	329 (0.84)	0.88 (0.77 to 1.00)	N/A
eGFR ≥90
DPP-4i, n=6330	28 (0.45)	0.79 (0.46 to 1.38)	0.37	61 (0.96)	0.90 (0.63 to 1.28)	0.53
SGLT2I, n=6485	23 (0.35)	0.79 (0.46 to 1.38)	0.37	56 (0.86)	0.90 (0.63 to 1.28)	0.53
eGFR 60 to <90
DPP-4i, n=22,625	95 (0.42)	1.10 (0.81 to 1.36)		194 (0.86)	0.94 (0.78 to 1.13)
SGLT2i, n=23,520	104 (0.44)	1.10 (0.81 to 1.36)		189 (0.80)	0.94 (0.78 to 1.13)
eGFR 45 to <60
DPP-4i, n=6198	28 (0.46)	1.00 (0.70 to 1.50)		68 (1.10)	0.82 (0.61 to 1.10)
SGLT2i, n=6577	31 (0.47)	1.00 (0.70 to 1.50)		59 (0.90)	0.82 (0.61 to 1.10)
eGFR 30 to <45
DPP-4i, n=2206	19 (0.88)	0.56 (0.30 to 1.06)		36 (1.64)	0.64 (0.43 to 0.95)
SGLT2i, n=2412	12 (0.50)	0.56 (0.30 to 1.06)		25 (1.04)	0.64 (0.43 to 0.95)

DPP-4i, dipeptidyl peptidase-4 inhibitor; SGLT2i, sodium-glucose cotransporter-2 inhibitor, eGFR, estimated glomerular filtration rate.